D-erythro MAPP (CAS 143492-38-0)
Alternate Names:
(1S,2R-D-erythro-2-N-Myristoylamino)-1-phenyl-1-propanol
CAS Number:
143492-38-0
Molecular Weight:
361.6
Molecular Formula:
C23H39NO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
D-erythro-MAPP is a synthetic analog of ceramide. Shown to selectively inhibit ASAH/APHC (alkaline ceramidase) both in vitro and in HL-60 cells (IC50 = 1-5 muM for ASAH/APHC (alkaline ceramidase) versus IC50 > 500 muM for acid ceramidase). D-erythro-MAPP′s inhibition results in over 3-fold increase in endogenous ceramide in treated cells due to lack of breackdown of ceramide to sphingosine.
D-erythro MAPP (CAS 143492-38-0) References
- Sphingolipids function as downstream effectors of a fungal PAQR. | Villa, NY., et al. 2009. Mol Pharmacol. 75: 866-75. PMID: 19066337
- The ATP-binding cassette transporter-2 (ABCA2) regulates esterification of plasma membrane cholesterol by modulation of sphingolipid metabolism. | Davis, W. 2014. Biochim Biophys Acta. 1841: 168-79. PMID: 24201375
- Characterization and Functional Analysis of Extracellular Vesicles and Muscle-Abundant miRNAs (miR-1, miR-133a, and miR-206) in C2C12 Myocytes and mdx Mice. | Matsuzaka, Y., et al. 2016. PLoS One. 11: e0167811. PMID: 27977725
- Inhibition of pannexin-1 channel activity by adiponectin in podocytes: Role of acid ceramidase activation. | Li, G., et al. 2018. Biochim Biophys Acta Mol Cell Biol Lipids. 1863: 1246-1256. PMID: 30077007
- Human alkaline ceramidase 2 promotes the growth, invasion, and migration of hepatocellular carcinoma cells via sphingomyelin phosphodiesterase acid-like 3B. | Liu, B., et al. 2020. Cancer Sci. 111: 2259-2274. PMID: 32391585
- The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines. | Field, BC., et al. 2020. Front Endocrinol (Lausanne). 11: 569250. PMID: 33133017
- Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. | İzgördü, H., et al. 2020. Cytotechnology. 72: 907-919. PMID: 33270814
- Correction to: Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. | İzgördü, H., et al. 2021. Cytotechnology. 73: 139-140. PMID: 33505121
- Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer. | Gomez-Larrauri, A., et al. 2021. Medicina (Kaunas). 57: PMID: 34357010
- S1P Signalling Axis Is Necessary for Adiponectin-Directed Regulation of Electrophysiological Properties and Oxidative Metabolism in C2C12 Myotubes. | Bernacchioni, C., et al. 2022. Cells. 11: PMID: 35203362
- Emerging Roles of Ceramides in Breast Cancer Biology and Therapy. | Pal, P., et al. 2022. Int J Mol Sci. 23: PMID: 36232480
- The Critical Impact of Sphingolipid Metabolism in Breast Cancer Progression and Drug Response. | Corsetto, PA., et al. 2023. Int J Mol Sci. 24: PMID: 36768427
- Enhancement of Sphingomyelinase-Induced Endothelial Nitric Oxide Synthase-Mediated Vasorelaxation in a Murine Model of Type 2 Diabetes. | Ruisanchez, É., et al. 2023. Int J Mol Sci. 24: PMID: 37176081
- Functional roles of sphingolipids in immunity and their implication in disease. | Lee, M., et al. 2023. Exp Mol Med. 55: 1110-1130. PMID: 37258585
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
D-erythro MAPP, 5 mg | sc-471415 | 5 mg | $62.00 |